 Amarin Corporation plc NASDAQ: AMRN reported new data for VascepaVazkepa icosapent ethyl at the American Heart Association AHA Scientific Sessions. The investigators concluded that Icosapent ethyl 4 gday significantly reduced total first and subsequent primary endpoints by 32, and trended toward a 22 reduction in first events, in patients with Peripheral Artery Disease PAD. 